Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
Collet L, Noël JC, Catteau X, Ardin M, Berthet J, Ghamry-Barrin S, Treilleux I, Bengrine Lefevre L, Martinez M, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O. Collet L, et al. Among authors: caux c. ESMO Open. 2025 Jun;10(6):105104. doi: 10.1016/j.esmoop.2025.105104. Epub 2025 Jun 4. ESMO Open. 2025. PMID: 40472658 Free PMC article. Clinical Trial.
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
Collet L, Ardin M, Venet D, Berthet J, Ghamry-Barrin S, Treilleux I, Noel JC, Leheurteur M, Meunier J, Bengrine Lefevre L, Martinez M, Priou F, Selle F, Just PA, Bataillon G, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O. Collet L, et al. Among authors: caux c. Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2712. Online ahead of print. Clin Cancer Res. 2025. PMID: 40378056
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma.
Gobbini E, Hubert M, Doffin AC, Eberhardt A, Hermet L, Li D, Duplouye P, Ghamry-Barrin S, Berthet J, Benboubker V, Grimont M, Sakref C, Perrot J, Tondeur G, Harou O, Lopez J, Dubois B, Dalle S, Caux C, Caramel J, Valladeau-Guilemond J. Gobbini E, et al. Among authors: caux c. Cancer Immunol Res. 2025 Apr 2;13(4):517-526. doi: 10.1158/2326-6066.CIR-24-0421. Cancer Immunol Res. 2025. PMID: 39774795
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.
Santagata S, Trotta AM, D'Alterio C, Napolitano M, Rea G, Di Napoli M, Portella L, Ieranò C, Guardascione G, Coppola E, Caux C, Dubois B, Boyle HJ, Carles J, Rossetti S, Azzaro R, Feroce F, Perdonà S, Fordellone M, Bello AM, Califano D, Chiodini P, Pignata S, Scala S. Santagata S, et al. Among authors: caux c. Clin Cancer Res. 2024 Oct 15;30(20):4755-4767. doi: 10.1158/1078-0432.CCR-24-0729. Clin Cancer Res. 2024. PMID: 39167621 Free PMC article.
246 results